(Q31096565)

28 June 2017

0 references

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data (English)

1 reference

chronic lymphocytic leukemia

28 June 2017

0 references

1 reference

1 reference

1 reference

1 reference

International CLL-IPI working group

series ordinal

1

1 reference

28 June 2017

publication date

13 May 2016

1 reference

Lancet Oncology Commission

28 June 2017

published in

1 reference

28 June 2017

volume

17

1 reference

28 June 2017

issue

6

1 reference

28 June 2017

page(s)

779-790

1 reference

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Mutations driving CLL and their evolution in progression and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Non-coding recurrent mutations in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

TP53 mutation and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

A new prognostic score for CLL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930029-8

7 January 2021

10.1016/S1470-2045(16)30029-8

Identifiers

DOI

1 reference

28 June 2017

1 reference